APG Research, LLC

Running trials

• Recruiting

  A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  NCT07424404· Phase 3· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  NCT07288567· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· Phase 3· Source

• Active, not recruiting

  ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

  NCT05889273· Phase 2· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia3 recruiting
• Autism2 recruiting
• Bipolar disorder1 recruiting
• Depression1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

  NCT06557902· Phase 1· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Source

• Terminated

  Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

  NCT05555615· Phase 2/3· Source

• Completed

  ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

  NCT05081245· Phase 2· Source

• Completed

  Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

  NCT05523895· Phase 2/3· Source

• Terminated

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

  NCT04951609· Phase 1· Source

• Completed

  Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

  NCT04745026· Phase 2· Source

• Terminated

  The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

  NCT04753385· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Source